Literature DB >> 28464134

Characteristics and Dissemination of Phase 1 Trials Approved by a UK Regional Office in 2012.

Ayodele Odutayo1, Bethan Copsey1, Susan Dutton1, Jonathan Cook1, Sally Hopewell1, Douglas G Altman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28464134      PMCID： PMC5815011          DOI： 10.1001/jama.2017.1471

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  3 in total

1.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors:  Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal:  N Engl J Med       Date:  2006-08-14       Impact factor: 91.245

2.  Implications of the BIA-102474-101 study for review of first-into-human clinical trials.

Authors:  Michael Eddleston; Adam F Cohen; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2016-04       Impact factor: 4.335

3.  Inadequate dissemination of phase I trials: a retrospective cohort study.

Authors:  Evelyne Decullier; An-Wen Chan; François Chapuis
Journal:  PLoS Med       Date:  2009-02-17       Impact factor: 11.069
  3 in total
  1 in total

1.  Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects.

Authors:  Dmitry Gryaznov; Ayodele Odutayo; Belinda von Niederhäusern; Benjamin Speich; Benjamin Kasenda; Elena Ojeda-Ruiz; Anette Blümle; Stefan Schandelmaier; Dominik Mertz; Yuki Tomonaga; Alain Amstutz; Christiane Pauli-Magnus; Viktoria Gloy; Karin Bischoff; Katharina Wollmann; Laura Rehner; Szimonetta Lohner; Joerg J Meerpohl; Alain Nordmann; Katharina Klatte; Nilabh Ghosh; Ala Taji Heravi; Jacqueline Wong; Ngai Chow; Patrick Jiho Hong; Kimberly Mc Cord; Sirintip Sricharoenchai; Jason W Busse; Arnav Agarwal; Ramon Saccilotto; Matthias Schwenkglenks; Giusi Moffa; Lars G Hemkens; Sally Hopewell; Erik von Elm; Matthias Briel
Journal:  Trials       Date:  2020-10-28       Impact factor: 2.279
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.